Inhibikase Therapeutics appoints Scott Wasserman to board

IKT•2026-10-20

Inhibikase Therapeutics appointed Scott M. Wasserman to its board, effective October 19, 2026. Dennis Berman resigned concurrently; Wasserman previously served as an Amgen vice president overseeing global development across several therapeutic areas.

1. Board appointment

Inhibikase Therapeutics appointed Scott M. Wasserman to its board effective October 19, 2026, as Dennis Berman resigned. Wasserman previously served as an Amgen vice president overseeing global development across several therapeutic areas.

Inhibikase Therapeutics appoints Scott Wasserman to board

1. Board appointment

Related News

JPMorgan Chase closes $7 billion floating-rate and fixed-to-floating-rate debt offering

Dogness falls out of compliance with Nasdaq minimum bid price requirement

Neptune Insurance Q3 net income jumps 50% on strong premium growth

ARMOUR Residential REIT announces November 2026 dividend of $0.24 per common share

Toro names Neal M. Lackritz chief technology officer, effective Nov. 2, 2026